RESULTS	Arm B : 39 evaluable patients yielded a 6-month survival rate of 41 % ( 16/39 , 95 % CI 29.8 % to 67.0 % ) , median survival of 4.8 months ( 95 % CI 2.4 -- 7.4 ) , median TTP of 2.4 months ( 95 % CI 1.5 -- 3.1 ) , and confirmed RR of 10 % ( 4 partial responses/0 complete responses , 95 % CI 3 % to 24 % ) .\